Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Overall improvement, severities and changes of specific clinical symptoms were surveyed in outpatients with depression or in a depressed state to evaluate the efficacy and safety of PAXIL tablets in patients in whom the PAXIL dose was increased and those treated with a constant dose.

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

• Subjects who is 18 years or more

• Subjects diagnosed with depression or in a depressed state

Exclusion Criteria:

• Subjects who have been treated with paroxetine prior to this investigation

• Subjects with hypersensitivity to paroxetine

• Subjects taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs

• Concomitant use in subjects taking pimozide